19, March 2020
Coronavirus: where do we stand in the race for a vaccine? 0
As the world races to find a vaccine or a cure for the coronavirus, antimalarial drugs, HIV medications, flu vaccines and arthritis treatments are all being tested. FRANCE 24 takes a look at the latest medical efforts to combat the pandemic.
Teams of scientists across the world are working around the clock to either develop a new drug or repurpose an existing medication to halt the spread of the virus.
Viruses are tiny parasitic bits of genetic material that replicate inside another organism. Vaccines for viruses such as measles are typically made from a weakened form of the virus. But this process can take years.
Scientists are now fast-tracking results and sidestepping normal scientific steps, such as animal testing, to find drugs that will treat and kill the virus that causes COVID-19.
How close are we to a vaccine?
China:
The first country to experience the virus and also the first to start searching for vaccines and cures, China is understandably leading the field in the hunt for a vaccine. On December 31 last year, China alerted the World Health Organization (WHO) to several cases of unusual pneumonia in Wuhan, a port city of 11 million people in Hubei province. The virus was at that point unknown.
To create an original vaccine, the Chinese company Beijing Advaccine Biotechnology is working with a US biotech company called Inovio Pharmaceuticals. They are in the process of developing a “DNA vaccine” called INO-4800.
This vaccine is already in preclinical trial. It involves directly injecting genetic material into a person to trigger a stronger immune response, so they are better equipped to stop an infection.
Japan:
On January 16, Japan became the first country to confirm a coronavirus case outside China.
Fujifilm may be best known for its photographic products, but the Japanese company also makes a drug called Favipiravir (capitalized). This was initially intended to treat new strains of the flu. However, it appears to be proving effective in treating coronavirus patients, particularly those with lighter symptoms.
Europe:
Germany’s BioNTech has been one of the major players in European vaccine developments. It announced on Monday that it is developing an experimental vaccine, working with Fosun Pharma in China. On Tuesday, it confirmed a collaboration with America’s largest pharmaceutical company, Pfizer, to develop the drug outside of China. They hope to be in a position to start testing the new vaccine early next month.
Reuters reported on Sunday that the German government was trying to stop the US administration from persuading CureVac, another German drugmaker working on an experimental vaccine for the coronavirus, to move its research to the United States. This prompted German politicians to insist that no country should have a monopoly on any future vaccine.
Earlier, the Welt am Sonntag German newspaper reported that US President Donald Trump had offered funds to lure CureVac to the United States, and the German government was making counter-offers to tempt it to stay.
Responding to the report, the U.S. ambassador to Germany, Richard Grenell, wrote on Twitter: “The Welt story was wrong.”
US:
The first human trials of a potential vaccine called mRNA-1273 have already begun in the United States. Their vaccine has been made by biotechnology company Moderna Therapeutics.
Four patients received injections of the vaccine at the Kaiser Permanente research facility in Seattle, Washington, the Associated Press news agency reported.
The early-stage study of mRNA-1273 is being carried out by the US National Institutes of Health.
Instead of creating the mRNA-1273 vaccine from the coronavirus, scientists have copied a short segment of genetic code from the virus.
To test this new drug as fast as possible, they have sidestepped normal procedures such as initially testing on animals. The initial trial is expected to involve 45 healthy adult volunteers between the ages of 18 and 55 years over approximately six weeks. It could take 12 months before any concrete results are produced.
How close are we to a cure?
China:
By the end of January, China was already exploring how existing drugs might be repurposed to kill the virus.
One of the first drugs China explored with some success was an antimalarial drug called chloroquine phosphate. Speaking at a press conference on February 18, Sun Yanrong, deputy head of the China National Centre for Biotechnology Development at the ministry of science and technology, said this drug has already been under clinical trial in more than 10 hospitals in Beijing as well as in Guangdong Province and in Hunan Province.
According to Sun, patients treated with chloroquine saw a greater drop in fever, an improvement in their lung scans and required a shorter time to recover compared to parallel groups.
Among other drugs currently being tested in China is a Swiss-made anti-inflammation drug called Tocilizumab that suppresses overreactions by the immune system.
Another interesting advance has been made with a US antiviral drug called remdesivir, which has had impressive results in tests with more than 200 extremely ill patients.
Remdesivir was developed by Gilead Sciences to treat Ebola patients. It had good results in laboratories and with animals but was less successful with tests out in the field. Nevertheless, global health authorities deem it the most promising of possible treatments for people with severe cases of the virus.
Europe:
French pharmaceutical company Sanofi has announced it is ready to offer millions of doses of an antimalarial drug to French authorities after “promising” initial trials.
Sanofi said it could potentially treat 300,000 COVID-19 patients with the antimalarial drug Plaquenil, a spokesperson for the laboratory told AFP, adding that the group was ready to work with French health authorities “to confirm these results”.
Sanofi and its partner Regeneron Pharmaceuticals Inc have also started a clinical trial of their rheumatoid arthritis drug Kevzara as a treatment for the virus, the companies said on Monday.
Testing for patients with mid-to-severe stages of the virus will begin immediately, and the companies anticipate the trial will test up to 400 patients.
United States:
The United States may have had a slow start, but it has now sprinted ahead in the race for a vaccine.
A key development in the battle against the virus has emerged from the Quantitative Biosciences Institute Coronavirus Research Group, based out of the University of California. This team of hundreds of scientists has identified more than 50 drugs already in circulation that may effectively treat people infected with the virus.
The group has taken a different approach from many of their peers. Rather than find drugs that attack the virus itself, they are exploring drugs that will protect the proteins in our own cells that the coronavirus depends on to thrive and reproduce. With this type of treatment, our own systems will fight the virus.
Such a project would typically take a minimum of two years to achieve the results that this working group, which includes 22 laboratories across the US, has managed in a few weeks.
Another major development is the use of the HIV combination treatment lopinavir-ritonavari. This is currently being used in trials in America and other countries across the world, including India.
However, amid all the scientific developments, there are also unfounded rumours. In a statement published on Monday, Johnson & Johnson said there is “no evidence” that its HIV drug Prezista had any effect against the coronavirus in response to unsubstantiated reports that the drug might be a cure.
The company said it was aware that some HIV treatments are being considered as options to treat patients diagnosed with COVID-19.
Johnson & Johnson did say, however, that it was “partnering with multiple organizations to support the development of research programs and fast-track solutions for COVID-19”.
Culled from France 24
19, March 2020
Southern Cameroons Crisis: A war criminal Biya might be, but his regime’s propaganda campaign has basically worked 0
For French Cameroun barons of the ruling CPDM party, it helps if the Biya regime propaganda is not only delivered by the government spokesman and Minister of Communication but independent analysts, media practitioners, academics, and politicians.
From the very beginning of the Southern Cameroons war, the Biya Francophone regime, assisted by French diplomatic and business interest, has run a very elaborate media battle to portray itself as the victim of an international conspiracy, wherein its only opponents are Boko Haram terrorists from Nigeria and Southern Cameroons separatists who are being used by the Anglophone Cameroon diaspora in Europe, South Africa and United States to destabilize the country.
The most important part of this Biya regime strategic messaging supported by the French government of President Emmanuel Macron is aimed at Europe and the US that are habouring both the Southern Cameroons powerful diaspora and the French Cameroun’s Brigade Anti- Sardinards. They want the USA and Europe to continue to see Biya as the only alternative to stability in the CEMAC region. They constantly say that the West should support the 87 year old.
A war criminal Biya might be, but the ruling CPDM propaganda is telling the world that Biya will continue to protect all Cameroonian minorities – his role in endangering British Southern Cameroonians by starting a sectarian war against the English speaking people and his economic war against the Bamilekes notwithstanding – and that Biya has no immediate plans to turn to China.
For the Francophone dictator and barons of his ruling CPDM crime syndicate, it helps if this propaganda is not only delivered by the Cameroon government spokesman and other cabinet ministers but independent analysts, journalists, academics, and politicians.
Recently, the Minister of Territorial Administration, Paul Atanga Nji threatened to expel NGOs and media organizations that are reporting to the world the exact situation in Southern Cameroons. The Interior Minister launched a scathing attack on Equinox TV that has so far provided the most balanced and fair coverage of the Cameroon political story accusing the management of haven received 5 billion FCFA from donors abroad.
Correspondingly, the Yaoundé regime’s favourite media houses include Vision 4 TV owned by acolytes of the regime and which specializes in mixing together conspiracy theories, half-truths and outright lies.
The propaganda machinery has successfully put aside the firm position that was adopted earlier by the US ambassador to Cameroon, Peter Henry Barlerin that President Biya should think about his legacy and step aside.
The international community is yet to draw any red line around the killings currently going on in Southern Cameroons and now with the outbreak of the coronavirus, the United States government has no intention of enforcing regime change in Yaounde.
The Biya regime’s propaganda campaign has basically worked as the US Assistant Secretary of State Tibor Peter Nagy Jr. is now expressing misgivings about the Southern Cameroons revolution and Biya’s continued stay in power despite President Trump’s determined efforts to reduce US military and economic support for the corrupt government in Yaounde.
By ignoring the Cameroon government army atrocities in Southern Cameroons and only finding areas of common interest – such as fighting Boko Haram in the Far North of French Cameroun and encouraging democracy (even if such common interests are illusory) – the US State Department is slowly but surely turning its back against the Ambazonian people.
Consequently, the Southern Cameroons Interim Government should and must step up its game and proceed in taking the battle inside French Cameroun.
By Soter Tarh Agbaw-Ebai